A Disintegrin And Metalloproteinase

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (10:30, 19 May 2024) (edit) (undo)
 
(43 intermediate revisions not shown.)
Line 1: Line 1:
-
[[Image:2ao7.png|left|200px|thumb|Crystal structure of A Disintegrin And Metalloproteinase [[2ao7]]]]
+
<StructureSection load='' size='350' side='right' scene='43/436101/Cv/2' caption='A Disintegrin And Metalloproteinase complex with sulfate [[2ao7]]'>
-
{{STRUCTURE_2ao7| PDB=2ao7 | SIZE=300| SCENE=A_Disintegrin_And_Metalloproteinase/Cv/1 |right|CAPTION=A Disintegrin And Metalloproteinase complex with sulfate [[2ao7]] }}
+
 +
== Function ==
 +
[[A Disintegrin And Metalloproteinase]] (ADAM) are peptidases which cleave off extracellular portions of transmembrane proteins. ADAM family members are numbered.<br />
 +
* '''ADAM10''' cleaves ephrin.<br />
 +
* '''ADAM13''' details are in [[Molecular Playground/ADAM13]].<br />
 +
* '''ADAM17''' (TACE or TNF-α converting enzyme) processes the tumor necrosis factor-α.<br />
 +
* '''ADAM33''' is implicated in asthma.<br />
 +
* '''ADAMTS''' is ADAM with thrombospondin motifs<ref>PMID:15554875</ref>. <br />
 +
* '''ADAMTS1''' has anti-angionenic activity<ref>PMID:10811842</ref>. <br />
 +
* '''ADAMTS4''' and '''ADAMTS5''' are involved in the degradation of aggrecan.<br />
 +
* '''ADAMTS13''' cleaves [[Von Willebrand Factor]] involved in blood clotting<ref>PMID:18762209</ref>.
 +
== Disease ==
-
 
+
ADAM inhibitors are used in anti-cancer therapy. '''ADAM10''' is a therapeutic target for cancer and inflammation <ref>PMID:19601831</ref>. '''ADAM17''' is a therapeutic target for multiple diseases <ref>PMID:19601834</ref>. '''ADAM33''' is implicated in asthma. '''ADAM33''' is a therapeutic target for asthma <ref>PMID:38396994</ref>. '''ADAMTS4''' is involved in various CNS pathologies<ref>PMID:28084617</ref>.
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
 
+
-
[[A Disintegrin And Metalloproteinase]] (ADAM) are peptidases which cleave off extracellular portions of transmembrane proteins. ADAM inhibitors are used in anti-cancer therapy. ADAM family members are numbered. ADAM10 cleaves ephrin. ADAM13 details in [[Molecular Playground/ADAM13]]. ADAM17 processes the tumor necrosis factor-α. ADAM33 is implicated in asthma. ADAMTS is ADAM with thrombospondin motifs. ADAMTS1 has anti-angionenic activity. ADAMTS4 and ADAMTS5 are involved in the degradation of aggrecan. ADAMTS13 cleaves von Willebrand factor involved in blood clotting. The images at the left and at the right correspond to one representative ADAM, ''i.e.'' the crystal structure of bovine A Disintegrin And Metalloproteinase 10 ([[2ao7]]).
+
-
 
+
-
{{TOC limit|limit=2}}
+
-
<br />
+
-
<br />
+
-
<br />
+
-
<br />
+
-
<br />
+
-
<br />
+
== 3D Structures of A Disintegrin And Metalloproteinase ==
== 3D Structures of A Disintegrin And Metalloproteinase ==
 +
[[A Disintegrin And Metalloproteinase 3D structures]]
-
''Update November 2011''
+
</StructureSection>
-
 
+
-
===ADAM5===
+
-
 
+
-
[[3hy7]], [[3hyg]] – hADAM5 catalytic domain (mutant) - human<br />
+
-
 
+
-
===ADAM10===
+
-
 
+
-
[[2ao7]] – ADAM10 - bovine<br />
+
-
+
-
===ADAM17===
+
-
 
+
-
[[1zxc]], [[2a8h]], [[2ddf]] – hADAM17 catalytic domain + inhibitor <br />
+
-
[[2fv5]], [[2fv9]], [[2i47]], [[3b92]], [[3cki]], [[3e8r]], [[3edz]], [[3ewj]], [[3g42]], [[3l0t]], [[3l0v]], [[3le9]], [[3lea]], [[3lgp]], [[3kmc]], [[3kme]], [[3o64]] - hADAM17 catalytic domain (mutant)+ inhibitor<br />
+
-
 
+
-
===ADAM22===
+
-
 
+
-
[[3g5c]] = hADAM22 ectodomain
+
-
 
+
-
===ADAM33===
+
-
 
+
-
[[1r54]], [[1r55]] – hADAM33 catalytic domain<br />
+
-
 
+
-
===ADAMTS1===
+
-
 
+
-
[[2jih]], [[3q2g]], [[3q2h]] - hADAMTS1 catalytic domain + inhibitor<br />
+
-
[[2v4b]] - hADAMTS1 catalytic domain
+
-
 
+
-
===ADAMTS4===
+
-
 
+
-
[[3b2z]] - hADAMTS4 residues 213-520<br />
+
-
[[2rjp]] - hADAMTS4 residues 213-520 (mutant) + inhibitor
+
-
 
+
-
===ADAMTS5===
+
-
 
+
-
[[2rjq]] - hADAMTS5 residues 262-628 + inhibitor<br />
+
-
[[3b8z]], [[3hy7]], [[3hyg]], [[3ljt]], [[3hy9]] - hADAMTS5 catalytic domain (mutant) + inhibitor
+
-
 
+
-
===ADAMTS13===
+
-
 
+
-
[[3ghm]], [[3ghn]] - hADAMTS13 exosite-containing fragment (mutant)
+
 +
== References ==
 +
<references/>
[[Category:Topic Page]]
[[Category:Topic Page]]

Current revision

A Disintegrin And Metalloproteinase complex with sulfate 2ao7

Drag the structure with the mouse to rotate

References

  1. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J. 2005 Feb 15;386(Pt 1):15-27. PMID:15554875 doi:10.1042/BJ20040424
  2. Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Nishimatsu H, Moriyama N, Oh-hashi Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K. ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest. 2000 May;105(10):1345-52. PMID:10811842 doi:10.1172/JCI8635
  3. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008 Oct;29(5):258-89. doi: 10.1016/j.mam.2008.08.001. Epub 2008, Aug 15. PMID:18762209 doi:http://dx.doi.org/10.1016/j.mam.2008.08.001
  4. Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des. 2009;15(20):2288-99. PMID:19601831 doi:10.2174/138161209788682442
  5. Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319-35. PMID:19601834 doi:10.2174/138161209788682398
  6. Sleziak J, Gawor A, Błażejewska M, Antosz K, Gomułka K. ADAM33's Role in Asthma Pathogenesis: An Overview. Int J Mol Sci. 2024 Feb 15;25(4):2318. PMID:38396994 doi:10.3390/ijms25042318
  7. Lemarchant S, Wojciechowski S, Vivien D, Koistinaho J. ADAMTS-4 in central nervous system pathologies. J Neurosci Res. 2017 Sep;95(9):1703-1711. PMID:28084617 doi:10.1002/jnr.24021

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky, Joel L. Sussman

Personal tools